Fibroblast growth factor 23/klotho axis in chronic kidney disease

Nephron - Clinical Practice

Volumn 128, Issue 1-2, 2014, Pages 1-10

  Nitta, Kosaku ^a   Nagano, Nobuo ^b   Tsuchiya, Ken ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^b Medical Corporations Hidaka Hospital Takasaki   (Japan)

Author keywords

CKD MBD; FGF23; Klotho; Phosphate; Vascular calcification

Indexed keywords

25 HYDROXYVITAMIN D; FIBROBLAST GROWTH FACTOR 23; FIBROBLAST GROWTH FACTOR RECEPTOR 1; KLOTHO PROTEIN; PARATHYROID HORMONE; PHOSPHATE; BETA GLUCURONIDASE; FIBROBLAST GROWTH FACTOR; MINERAL;

ALTERNATIVE RNA SPLICING; BIOLOGICAL ACTIVITY; BLOOD VESSEL CALCIFICATION; CHRONIC KIDNEY DISEASE; CHRONIC KIDNEY FAILURE; ENZYME LINKED IMMUNOSORBENT ASSAY; HEMODIALYSIS PATIENT; HUMAN; KIDNEY FUNCTION; MINERAL METABOLISM; OBSERVATIONAL STUDY; PARATHYROID GLAND; PARATHYROIDECTOMY; PHOSPHATE BLOOD LEVEL; PRIMARY HYPERPARATHYROIDISM; PRIORITY JOURNAL; PROTEIN SECRETION; REVIEW; VITAMIN D METABOLISM; BLOOD; METABOLISM; PHYSIOLOGY; PROSPECTIVE STUDY;

FIBROBLAST GROWTH FACTORS; GLUCURONIDASE; HUMANS; MINERALS; PROSPECTIVE STUDIES; RENAL INSUFFICIENCY, CHRONIC;

EID: 84927599494     PISSN: None     EISSN: 16602110     Source Type: Journal    
DOI: 10.1159/000365787     Document Type: Review

References (88)

1. Sarnak M, Levey A, Schoolwerth A, Coresh J, Culleton B, Hamm LL, et al: Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on kidney in cardiovascular disease, high blood pressure research, and epidemiology and prevention. Circulation 2003; 108:2154-2169.
2. Weiner DE, Tighiouart H, Amin MG, Stark PC, MacLeod B, Griffith JL, et al: Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies. J Am Soc Nephrol 2004; 15:1307-1315.
3. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296-1305.
4. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group: KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl 2009; 113:S1-S130.
5. Yamashita T, Yoshioka M, Itoh N: Identification of a novel fibroblast growth factor, FGF23, preferentially expressed in the ven-trolateral thalamic nucleus of the brain. Bio-chem Biophys Res Commun 2000; 277:494-498.
6. Riminucci M, Collins MT, Fedarko NS, Cher-man N, Corsi A, White KE, et al: FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting. J Clin Invest 2003; 112:683-692.
7. Pereira RC, Juppner H, Azucena-Serrano CE, Yadin O, Salusky IB, Wesseling-Perry K: Patterns of FGF-23, DMP1, and MEPE expression in patients with chronic kidney disease. Bone 2009; 45:1161-1168.
8. Yamashita T: Structural and biochemical properties of fibroblast growth factor 23. Ther Apher Dial 2005; 9:313-318.
9. Quarles LD: Endocrine functions of bone in mineral metabolism regulation. J Clin Invest 2008; 118:3820-3828.
10. Bai XY, Miao D, Goltzman D, Karaplis AC: The autosomal dominant hypophosphatemic rats R176Q mutation in fibroblast growth factor 23 resists proteolytic cleavage and enhances in vivo biological potency. J Biol Chem 2003; 278:9843-9849.
11. Larsson T, Marsell R, Shipani E, Ohlsson C, Ljunggren O, Tenenhouse HS, et al: Trans-genic mice expressing fibroblast growth factor 23 under the control of the α1(I) collagen promoter exhibit growth retardation, osteo-malacia, and disturbed phosphate homeosta-sis. Endocrinology 2004; 145:3087-3094.
12. Shimada T, Urakawa I, Yamazaki Y, Hasega-wa H, Hino R, Yoneya T, et al: FGF23 trans-genic mice demonstrate hypophosphatemic rickets with reduced expression of sodium phosphate cotransporter type IIa. Biochem Biophys Res Commun 2004; 314:409-414.
13. Bai X, Miao D, Li J, Goltzman D, Karaplis AC: Transgenic mice overexpressing human fi-broblast growth factor 23 (R176Q) delineate a putative role for parathyroid hormone in renal phosphate wasting disorders. Endocrinology 2004; 145:5269-5279.
14. Segawa H, Kawakami E, Kaneko I, Kuwahata M, Ito M, Kusano K, et al: Effect of hydrolysis-resistant FGF23-R179Q on dietary phosphate regulation of the renal type II Na/Pi transporter. Pflugers Arch 2003; 446:585-592.
15. Shimada T, Hasegawa H, Yamazaki Y, Muto T, Hino R, Takeuchi Y, et al: FGF23 is a potent regulator of the vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 2004; 19:429-435.
16. Sitara D, Razzaque MS, Hesse M, Yoganathan S, Taguchi T, Erben RG, et al: Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeleto-genesis, and reverse hypophosphatemia in Phex-deficient mice. Matrix Biol 2004; 23: 421-432.
17. Shimada T, Kakitani M, Yamazaki Y, Hasega-wa H, Takeuchi Y, Fujita T, et al: Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest 2004; 113: 561-568.
18. Khosravi A, Cutler CM, Kelly MH, Chang R, Royal RE, Sherry RM, et al: Determination of the elimination half-life of fibroblast growth factor-23. J Clin Endocrinol Metab 2007; 92: 2374-2377.
19. Yamazaki Y, Okazaki R, Shibata M, Hasegawa Y, Satoh K, Tajima T, et al: Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. J Clin Endocrinol Metab 2002; 87:4957-4960.
20. Ibrahim S, Rashed L: Serum fibroblast growth factor-23 levels in chronic haemodialysis patients. Int Urol Nephrol 2009; 41:163-169.
21. Gutierrez O, Isakova T, Rhee E, Shah A, Holmes J, Collerone G, et al: Fibroblast growth factor-23 mitigates hyperphosphate-mia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol 2005; 16:2205-2215.
22. Isakova T, Xie H, Yang W, Xie D, Anderson AH, Scialla J, et al: Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA 2011; 305:2432-2439.
23. Kuro-o M, Matsumura Y, Aizawa H, Kawagu-chi H, Suga T, Utsugi T, et al: Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 1997; 390:45-51.
24. Tsujikawa H, Kurotaki Y, Fujimori T, Fukuda K, Nabeshima Y: Klotho, a gene related to a syndrome resembling human premature ageing, functions in a negative regulatory circuit of vitamin D endocrine system. Mol Endocri-nol 2003; 17:2393-2403.
25. Kurosu H, Ogawa Y, Miyoshi M, Yamamoto M, Nandi A, Rosenblatt KP, et al: Regulation of fibroblast growth factor-23 signaling by klotho. J Biol Chem 2006; 281:6120-6123.
26. Urakawa I, Yamazaki Y, Shimada T, Iijima K, Hasegawa H, Okawa K, et al: Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 2006; 444:770-774.
27. Lau WL, Leaf EM, Hu MC, Takeno MM, Kuro-o M, Moe OW, et al: Vitamin D receptor agonists increase klotho and osteopon-tin while decreasing aortic calcification in mice with chronic kidney disease fed a high phosphate diet. Kidney Int 2012; 82:1261-1270.
28. Farrow EG, Davis SI, Summers LJ, White KE: Initial FGF23-mediated signaling occurs in the distal convoluted tubule. J Am Soc Nephrol 2009; 20:955-960.
29. Hu MC, Shi M, Zhang J, Pastor J, Nakatani T, Lanske B, et al: Klotho: a novel phosphaturic substance acting as an autocrine enzyme in the renal proximal tubule. FASEB J 2010; 24: 3438-3450.
30. Krajisnik T, Björklund P, Marsell R, Ljung-gren O, Akerstrom G, Jonsson KB, et al: Fi-broblast growth factor-23 regulates parathyroid hormone and 1-hydroxylase expression in cultured bovine parathyroid cells. J Endo-crinol 2007; 195:125-131.
31. Kawata T, Imanishi Y, Kobayashi K, Miki T, Arnold A, Inaba M, et al: Parathyroid hormone regulates fibroblast growth factor-23 in a mouse model of primary hyperparathyroid-ism. J Am Soc Nephrol 2007; 18:2683-2688.
32. Ben-Dov IZ, Galitzer H, Lavi-Moshayoff V, Goetz R, Kuro-o M, Mohammadi M, et al: The parathyroid is a target organ for FGF23 in rats. J Clin Invest 2007; 117:4003-4008.
33. Imura A, Iwano A, Tohyama O, Tsuji Y, No-zaki K, Hashimoto N, Fujimori T, et al: Secreted Klotho protein in sera and CSF: implication for post-translational cleavage in release of Klotho protein from cell membrane. FEBS Lett 2004; 565:143-147.
34. Kurosu H, Yamamoto M, Clark JD, Pastor JV, Nandi A, Gurnani P, et al: Suppression of aging in mice by the hormone Klotho. Science 2005; 309:1829-1833.
35. Chen CD, Podvin S, Gillespie E, Leeman SE, Abraham CR: Insulin stimulates the cleavage and release of the extracellular domain of Klotho by ADAM10 and ADAM17. Proc Natl Acad Sci USA 2007; 104:19796-19801.
36. Hu MC, Shi M, Zhang J, Quinones H, Griffith C, Kuro-o M, et al: Klotho deficiency causes vascular calcification in chronic kidney disease. J Am Soc Nephrol 2011; 22:124-136.
37. Cha SK, Ortega B, Kurosu H, Rosenblatt KP, Kuro-o M, Huang CL: Removal of sialic acid involving Klotho causes cell-surface retention of TRPV5 channel via binding to galectin-1. Proc Natl Acad Sci USA 2008; 105:9805-9810.
38. Chang Q, Hoefs S, van der Kemp AW, To-pala CN, Bindels RJ, Hoenderop JG: The β-glucuronidase klotho hydrolyzes and activates the TRPV5 channel. Science 2005; 310: 490-493.
39. Liu H, Fergusson MM, Castilho RM, Liu J, Cao L, Chen J, et al: Augmented Wnt signaling in a mammalian model of accelerated aging. Science 2007; 317:803-806.
40. Doi S, Zou Y, Togao O, Pastor JV, John GB, Wang L, et al: Klotho inhibits transforming growth factor-β 1 (TGF-β 1) signa ling and suppresses renal fibrosis and cancer metastasis in mice. J Biol Chem 2011; 286:8655-8665.
41. Cozzolino M, Galassi A, Galliei M, Brancac-cio D: Pathogenesis and treatment of secondary hyperparathyroidism in dialysis patients: the role of paricalcitol. Curr Vasc Pharmacol 2008; 6:148-153.
42. Stubbs JR, He N, Idiculla A, Gillihan R, Liu S, David V, et al: Longitudinal evaluation of FGF23 changes and mineral metabolism abnormalities in a mouse model of chronic kidney disease. J Bone Miner Res 2012; 27:38-46.
43. Nagano N, Miyata S, Abe M, Kobayashi N, Wakita S, Yamashita T, et al: Effect of manipulating serum phosphorus with phosphate binder on circulating PTH and FGF23 in renal failure rats. Kidney Int 2006; 69:531-537.
44. Fliser D, Kollerits B, Neyer U, Ankerst DP, Lhotta K, Lingenhel A, et al: Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study. J Am Soc Nephrol 2007; 18:2600-2608.
45. Larsson T, Nisbeth U, Ljunggren O, Juppner H, Jonsson KB: Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int 2003; 64:2272-2279.
46. Nakano C, Hamano T, Fujii N, Obi Y, Matsui I, Tomida K, et al: Combined use of vitamin D status and FGF23 for risk stratification of renal outcome. Clin J Am Soc Nephrol 2012; 7:810-819.
47. Koh N, Fujimori T, Nishiguchi S, Tamori A, Shiomi S, Nakatani T, et al: Severely reduced production of klotho in human chronic renal failure kidney. Biochem Biophys Res Com-mun 2001; 280:1015-1020.
48. Seiler S, Heine GH, Fliser D: Clinical relevance of FGF-23 in chronic kidney disease. Kidney Int Suppl 2009; 114:S34-S42.
49. Lavi-Moshayoff V, Silver J, Naveh-Many T: Human PTH gene regulation in vivo using transgenic mice. Am J Physiol Renal Physiol 2009; 297:F713-F719.
50. Razzaque MS, Lanske B: The emerging role of the fibroblast growth factor-23-klotho axis in renal regulation of phosphate homeostasis. J Endocrinol 2007; 194:1-10.
51. Haruna Y, Kashihara N, Satoh M, Tomita N, Namikoshi T, Sasaki T, et al: Amelioration of progressive renal injury by genetic manipulation of Klotho gene. Proc Natl Acad Sci USA 2007; 104:2331-2336.
52. Wang Y, Sun Z: Klotho gene delivery prevents the progression of spontaneous hypertension and renal damage. Hypertension 2009; 54: 810-817.
53. Hu MC, Kuro-o M, Moe OW: Klotho and kidney disease. J Nephrol 2010; 23(suppl 16): S136-S144.
54. Zhao Y, Banerjee S, Dey N, LeJeune WS, Sarkar PS, Brobey R, et al: Klotho depletion contributes to increased inflammation in kidney of the db/db mouse model of diabetes via RelA (serine)536 phosphorylation. Diabetes 2011; 60:1907-1916.
55. Hu MC, Kuro-o M, Moe OW: Secreted klotho and chronic kidney disease. Adv Exp Med Biol 2012; 728:126-157.
56. Asai O, Nakatani K, Tanaka T, Sakan H, Imu-ra A, Yoshimoto S, et al: Decreased renal α-Klotho expression in early diabetic ne-phropathy in humans and mice and its possible role in urinary calcium excretion. Kidney Int 2012; 81:539-547.
57. Yamazaki Y, Imura A, Urakawa I, Shimada T, Murakami J, Ando Y, et al: Establishment of sandwich ELISA for soluble α-Klotho measurement: age-dependent change of soluble α-Klotho levels in healthy subjects. Biochem Biophys Res Commun 2010; 398:513-518.
58. Shimamura Y, Hamada K, Inoue K, Ogata K, Ishihara M, Kagawa T, Inoue M, et al: Serum levels of soluble α-Klotho are decreased in the early stages of chronic kidney disease, making it a probable novel biomarker for early diagnosis. Clin Exp Nephrol 2012; 16:722-729.
59. Gutierrez OM, Ix JH: α-Klotho and kidney function decline: an important step forward in understanding the link between mineral metabolism and kidney disease progression. Am J Kidney Dis 2013; 61:855-857.
60. Kim HR, Nam BY, Kim DW, Kang MW, Han JH, Lee MJ, et al: Circulating α-klotho levels in CKD and relationship to progression. Am J Kidney Dis 2013; 61:899-909.
61. Seiler S, Wen M, Roth HJ, Fehrenz M, Flügge F, Herath E, et al: Plasma Klotho is not related to kidney function and does not predict adverse outcome in patients with chronic kidney disease. Kidney Int 2013; 83:121-128.
62. Hu MC, Shiizaki K, Kuro-o M, Moe OW: Fi-broblast growth factor 23 and Klotho: physiology and pathophysiology of an endocrine network of mineral metabolism. Annu Rev Physiol 2013; 75:503-533.
63. Pavik I, Jaeger P, Ebner L, Wahner CA, Pet-zold K, Spichtig D, et al: Secreted Klotho and FGF23 in chronic kidney disease stages 1 to 5: a sequence suggested from a cross-sectional study. Nephrol Dial Transplant 2013; 28:352-359.
64. Akimoto T, Yoshizawa H, Watanabe Y, Nu-mata A, Yamazaki T, Takeshima E, et al: Characteristics of urinary and serum soluble Klotho protein in patients with different degrees of chronic kidney disease. BMC Nephrol 2012; 13:155.
65. Sakan H, Nakatani K, Asai O, Imura A, Tana-ka T, Yoshimoto S, et al: Reduced renal α-Klotho expression in CKD patients and its effect on renal phosphate handling and vitamin D metabolism. PLoS One 2014; 9:e86301.
66. Coresh J, Astor B, Sarnak MJ: Evidence for increased cardiovascular disease risk in patients with chronic kidney disease. Curr Opin Nephrol Hypertens 2004; 13:73-81.
67. Kendrick J, Chonchol MB: Nontraditional risk factors for cardiovascular disease in patients with chronic kidney disease. Nat Clin Pract Nephrol 2008; 4:672-681.
68. Moe SM, Chen NX: Mechanisms of vascular calcification in chronic kidney disease. J Am Soc Nephrol 2008; 19:213-216.
69. Cannata-Andia JB, Rodriguez-Garcia M, Carrillo-Lopez N, Naves-Diaz M, Diaz-Lopez B: Vascular calcifications: pathogenesis, management, and impact on clinical outcomes. J Am Soc Nephrol 2006; 17(suppl 3):S267-S273.
70. Nitta K: Vascular calcification in patients with chronic kidney disease. Ther Apher Dial 2011; 15:513-521.
71. Nakatani T, Sarraj B, Ohnishi M, Densmore MJ, Taguchi T, Goetz R, et al: In vivo genetic evidence for klotho-dependent, fibroblast growth factor 23 (Fgf23)-mediated regulation of systemic phosphate homeostasis. FASEB J 2009; 23:433-441.
72. De Schutter TM, Neven E, Persy VP, Behets GJ, Postnov AA, Clerck NM, et al: Vascular calcification is associated with cortical bone loss in chronic renal failure rats with and without ovariectomy: the calcification paradox. Am J Nephrol 2011; 34:356-366.
73. Shiraki-Iida T, Iida A, Nabeshima Y, Anaza-wa H, Nishikawa S, Noda M, et al: Improvement of multiple pathophysiological pheno-types of klotho (kl/kl) mice by adenovirus-mediated expression of the klotho gene. J Gene Med 2000; 2:233-242.
74. Lau WL, Festing MH, Giachelli CM: Phosphate and vascular calcification: emerging role of the sodium-dependent phosphate co-transporter PiT-1. Thromb Haemost 2010; 104:464-470.
75. De Oliveira RM: Klotho RNAi induces premature senescence of human cells via a p53/p21-dependent pathway. FEBS Lett 2006; 580: 5753-5758.
76. Nakano-Kurimoto R, Ikeda K, Uraoka M, Na-kagawa Y, Yutaka K, Koide M, et al: Replica-tive senescence of vascular smooth muscle cells enhances the calcification through initiating the osteoblastic transition. Am J Physiol Heart Circ Physiol 2009; 297:H1673-H1684.
77. Lim K, Lu TS, Molostvov G, Lee C, Lam FT, Zehnder D, et al: Vascular Klotho deficiency potentiates the development of human artery calcification and mediates resistance to FGF-23. Circulation 2012; 125:2243-2255.
78. Scialla JJ, Lau WL, Reilly MO, Isakova T, Yang HY, Crouthamel MH, et al: Fibroblast growth factor 23 is not associated with and does not induce arterial calcification. Kidney Int 2013; 83:1159-1168.
79. Lindberg K, Olauson H, Amin R, Ponnusamy A, Goetz R, Taylor RF, et al: Arterial klotho expression and FGF23 effects on vascular calcification and function. PLoS One 2013; 8: e60658.
80. Goetz R, Nakada Y, Hu MC, Kurosu H, Wang L, Nakatani T, et al: Isolated C-terminal tail of FGF23 alleviates hypophosphatemia by inhibiting FGF23-FGFR-Klotho complex formation. Proc Natl Acad Sci USA 2010; 107: 407-412.
81. Razzaque MS: Therapeutic potential of klotho-FGF23 fusion polypeptides: WO2009095372. Expert Opin Ther Pat 2010; 20: 981-985.
82. Hasegawa H, Nagano N, Urakawa I, Yamaza-ki Y, Iijima K, Fujita T, et al: Direct evidence for a causative role of FGF23 in the abnormal renal phosphate handling and vitamin D metabolism in rats with early-stage chronic kidney disease. Kidney Int 2010; 78:975-980.
83. Shalhoub V, Shatzen EM, Ward SC, Davis J, Stevens J, Bi V, et al: FGF23 neutralization improves secondary hyperparathyroidism and osteodystrophy parameters yet exacerbates vascular calcification in chronic kidney disease rats. J Clin Invest 2012; 122:2543-2553.
84. Dominquez JR, Shlipak MG, Whooley MA, Ix JH: Fractional excretion of phosphorus modifies the association between fibroblast growth factor-23 and outcomes. J Am Soc Nephrol 2013; 24:647-654.
85. Hu MC, Shi M, Zhang J, Quinones H, Kuro-o M, Moe OW: Klotho deficiency is an early biomarker of renal ischemia-reperfusion injury and its replacement is protective. Kidney Int 2010; 78:1240-1251.
86. Sugiura H, Yoshida T, Mitobe M, Yoshida S, Shiohira S, Nitta K, et al: Klotho reduces apoptosis in experimental ischaemic acute kidney injury via HSP-70. Nephrol Dial Transplant 2010; 25:60-68.
87. Morishita K, Shirai A, Kubota M, Katakura Y, Nabeshima Y, Takeshige K, et al: The progression of aging in klotho mutant mice can be modified by dietary phosphorus and zinc. J Nutr 2001; 131:3182-3188.
88. Mitani H, Ishizaka N, Aizawa T, Ohno M, Usui S, Suzuki T, et al: In vivo klotho gene transfer ameliorates angiotensin II-induced renal damage. Hypertension 2002; 39:838-843.